Clinical trials: Degenerative Neurologic Disease
Mild Cognitive Impairment, Mild Dementia
The Use of Transcranial Focused Ultrasound for the Treatment of Neurodegenerative Dementias
The purpose of this open label study is to evaluate longer term tolerability and early efficacy of transcranial ultrasound in the treatment of patients with mild cognitive impairment or dementia.
- Conditions
- Mild Cognitive Impairment, Mild Dementia, Parkinson Disease, Alzheimer Disease
- Trial name
- NCT04250376
- Testing
- Focused Transcranial Ultrasound
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Neurological Associates of West Los Angeles
Alzheimer's Disease, Healthy
PET Imaging of Brain Amyloid Using [11C]MeS-IMPY
Alzheimer's disease is associated with accumulation in the brain of a protein called amyloid. The purpose of this study is to test the ability of a research drug to measure amyloid in brain using positron emission tomography…
- Trial name
- NCT00407576
- Testing
- [11C]MeS-IMPY
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Parkinson's Disease
Vibrotactile Stimulation in Parkinson's Disease
The purpose of this study is to examine the possibility of a new, non-invasive, non-drug treatment for Parkinson's disease. The treatment involves gentle vibratory stimulation delivered to the fingertips (called 'vibrotactile…
- Trial name
- NCT02933476
- Testing
- Vibrotactile Stimulation
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Stanford University
Tremor, Parkinson Disease
Open Label Study for the Use of Transcranial Ultrasound Treatment of Tremor
The purpose of this Phase I open label study is to evaluate longer term tolerability and potential effectiveness of transcranial ultrasound in people with tremor as a results of Parkinson's Disease or Essential Tremor.
- Conditions
- Tremor, Parkinson Disease, Essential Tremor
- Trial name
- NCT05475340
- Testing
- Focused Ultrasound
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Neurological Associates of West Los Angeles
Alzheimer Disease
Electrophysiologic Measures of Treatment Response in Alzheimer Disease
The main purpose of this study is to determine the electrophysiological effects of cholinergic therapy (cholinesterase inhibitors and transdermal nicotine) in Alzheimer disease.
- Trial name
- NCT00018278
- Testing
- Aricept, Exelon, Nicoderm Patch
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Alzheimer Disease, Amyloid Angiopathy
Comparison of OCTA Factors in Patients With or Without Amyloid Pathology: A Prospective Study
To compare alternation of retinal microcirculation within the macula and optic disc in patients with dementia, mild cognitive impairment (MCI), and cognitively healthy subjects who had positive amyloid biomarkers (Aβ +) or not…
- Conditions
- Alzheimer Disease, Amyloid Angiopathy, Macular Ischemia, Dementia
- Trial name
- NCT05475158
- Where
- South Korea
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Pusan National University Hospital
Alzheimer Disease (AD)
Generation of Synthetic [18F]FDG PET From Early-Phase Amyloid PET in Alzheimer's Disease
This study aims to test a new artificial intelligence (AI) method to create brain scan images without needing an extra scan. Currently, patients with memory problems often undergo two types of PET scans (Amyloid PET and FDG PET)…
- Trial name
- NCT07431255
- Where
- Italy
- Volunteers
- 35 people
- Sponsor
- IRCCS San Raffaele
Leber Hereditary Optic Neuropathy (LHON)
Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND4 Mutations
The objective of this clinical study is to evaluate the safety and efficacy of NR082 in the treatment of LHON caused by mitochondrial ND4 gene mutation.
- Trial name
- NCT05293626
- Testing
- NR082 Injection, Injection needle
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Neurophth Therapeutics Inc
Alzheimer's Disease
A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK933776) in Patients With Alzheimer's Disease
A study to investigate the safety and tolerability of both single and multiple intravenous administration of GSK933776 in patients with Alzheimer's Disease.
- Trial name
- NCT00459550
- Testing
- GSK933776
- Where
- 7 sites in Australia, Norway and 1 more
- Volunteers
- 50 people
- Sponsor
- GlaxoSmithKline
Motor Neuron Disease
EncoreAnywhere Use in Motor Neurone Disease
Motor neurone disease is a progressive incurable disease causing weakness and paralysis of muscles. Respiratory failure is the most common cause of death in motor neurone disease.
- Trial name
- NCT03154450
- Testing
- EncoreAnywhere with data available to review, EncoreAnywhere with no data available to review
- Where
- United Kingdom
- Volunteers
- 19 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Parkinson's Disease, Motor Symptoms
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
This study is designed to assess the effect of APOKYN treatment in rapid and reliable improvement of motor symptoms in Parkinson's disease (PD) subjects suffering from delayed or unreliable onset of levodopa (L-dopa) action.
- Conditions
- Parkinson's Disease, Motor Symptoms, Akinesia, Hypomobility
- Trial name
- AM IMPAKT (NCT01770145)
- Testing
- APOKYN, L-dopa, Trimethobenzamide
- Where
- 12 sites in United States
- Volunteers
- 127 people
- Sponsor
- MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
IBM, Inclusion Body Myositis
Imaging Assessment of Swallowing and Speech Muscles in Inclusion Body Myositis
This study will evaluate whether neuromuscular ultrasound and MRI can be used as imaging markers of bulbar involvement and swallowing dysfunction in individuals with inclusion body myositis (IBM).
- Conditions
- IBM, Inclusion Body Myositis, Myopathy, Myositis
- Trial name
- NCT07823101
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Cognitive Dysfunction, Cognitive Dysfunction, Cognitive Disorder
China-NINE Cohort：Neuroimmune Network in Elderly / Neurodegeneration
This is an observational study aimed at understanding the cognitive, functional, and behavioral characteristics of Chinese patients with cognitive impairment, exploring the underlying mechanisms, and providing evidence for early…
- Conditions
- Cognitive Dysfunction, Cognitive Dysfunction, Cognitive Disorder, Parkinson's Disease (PD)
- Trial name
- NCT07586501
- Where
- 2 sites in China
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Yantai Yuhuangding Hospital
Alzheimer Disease
Use of a Cannabinoids as a Treatment Strategy for Alzheimer's Disease
Brief Summary: The objective of the study is to evaluate the effect of cannabinoids on Alzheimer's Disease. This is a double-blind, randomized, placebo-controlled clinical trial.
- Trial name
- DAZACANN (NCT06570928)
- Testing
- Cannabis
- Where
- Brazil
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Federal University of Latin American Integration
Alzheimer's Disease
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Background: Normal aging, as well as dementias such as Alzheimer s disease, can cause changes in the brain that affect memory, attention, and thinking.
- Trial name
- NCT07721467
- Testing
- Psilocybin, Cognitive Training
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Institute on Aging (NIA)
Vitamin D Deficiency
Optimization of Blood Levels of 25(OH)-Vitamin D in African Americans
Two-thirds of the US population, particularly African Americans (AA), is at risk for inadequate or deficient 25-hydroxy-vitamin D (25(OH)VD).
- Trial name
- NCT04939792
- Testing
- Vitamin D, Vitamin D + L-cysteine, L-cysteine
- Where
- United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Louisiana State University Health Sciences Center Shreveport
Hypotension Symptomatic, Parkinson's Disease
Epidural Electrical Stimulation to Support Hemodynamic Management in Individuals With Parkinson's Disease
The PD-HemON study aims to evaluate the safety and preliminary efficacy of ARC-IM Therapy (Epidural Electrical Stimulation) to support hemodynamic management in people with typical and atypical Parkinson's Disease, who suffer…
- Conditions
- Hypotension Symptomatic, Parkinson's Disease, Orthostatic Hypotension, Dysautonomic, Multiple System Atrophy (MSA) With Orthostatic Hypotension
- Trial name
- PD-HemON (NCT06920134)
- Testing
- ARC-IM Investigational System
- Where
- Switzerland
- Volunteers
- 5 people
- Sponsor
- Ecole Polytechnique Fédérale de Lausanne
Progressive Supranuclear Palsy
Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011
The study will be conducted by the Sponsor to evaluate Twelve-months Long-Term Safety and Efficacy of GV1001 (1.12 mg) administered subcutaneously as a treatment for Progressive Supranuclear Palsy(PSP).
- Trial name
- NCT06235775
- Testing
- GV1001 1.12mg
- Where
- 5 sites in South Korea
- Volunteers
- 67 people
- Sponsor
- GemVax & Kael
Mild Cognitive Disorder, Alzheimer Disease
Digital Dementia Registry Bavaria (digiDEM Bayern): a Multicentre, Prospective, Longitudinal Register Study Including People With Mild Cognitive Impairment and Dementia as Well as Their Family Caregivers
Around 57 million people worldwide live with dementia, with approximately 10 million new cases diagnosed each year. By the end of 2023, around 1.8 million people were living with dementia in Germany, the majority of whom were…
- Conditions
- Mild Cognitive Disorder, Alzheimer Disease, Vascular Dementia, Dementia in Other Diseases Classified Elsewhere
- Trial name
- digiDEM Bayern (NCT07721701)
- Where
- 12 sites in Germany
- Volunteers
- 5,000 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Cerebrovascular Disorders, Brain Tumours
Environmental Pollutants and Neurological Disorders
Environmental pollutants have emerged as a major global health concern, with growing evidence linking exposure to both traditional contaminants such as heavy metals (lead, mercury, cadmium, arsenic) and novel pollutants-including…
- Conditions
- Cerebrovascular Disorders, Brain Tumours, Alzheimer Dementia
- Trial name
- CLEAN (NCT07140601)
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Beijing Tiantan Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.